AI assistant
Oric Pharmaceuticals, Inc. — Director's Dealing 2021
May 14, 2021
32131_dirs_2021-05-13_89099257-5357-4766-bcf1-99a25fc3fafd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Oric Pharmaceuticals, Inc. (ORIC)
CIK: 0001796280
Period of Report: 2021-05-11
Reporting Person: SCHELLER RICHARD H (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-11 | Common Stock | S | 300 | $25.1596 | Disposed | 49200 | Direct |
| 2021-05-12 | Common Stock | S | 103 | $25.0038 | Disposed | 49097 | Direct |
| 2021-05-13 | Common Stock | S | 100 | $25.00 | Disposed | 48997 | Direct |
Footnotes
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: Represents the weighted average share price of an aggregate total of 300 shares sold in the price range of $25.09 to $25.27 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3: Represents the weighted average share price of an aggregate total of 103 shares sold in the price range of $25.00 to $25.13 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.